Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
January 30, 2019
RegMed Investors’ (RMi) closing bell: investors need to comprehend the refracting light in the prism of share pricing
January 29, 2019
RegMed Investors’ (RMi) pre-open: sector risks vary resulting from low volume and steep declines
January 28, 2019
RegMed Investors’ (RMi) closing bell: retracement is more than a temporary reversal
January 17, 2019
RegMed Investors’ (RMi) closing bell: risky business
January 4, 2019
RegMed Investors’ (RMi) pre-open: it’s a bird, it’s a plane; no it’s a sector stock
January 3, 2019
RegMed Investors’ (RMi) closing bell: anxiety is piling on!
December 28, 2018
RegMed Investors’ (RMi) closing bell: sector stocks are volume centric and sensitive
December 27, 2018
RegMed Investors’ (RMi) pre-open: key word in three (3) trading sessions left in the year
December 26, 2018
RegMed Investors’ (RMi) closing bell: there was a Santa Claus rally after all, even if a day late
December 19, 2018
RegMed Investors’ (RMi) closing bell: oversold as market dips and picks-up at the close leaving the sector sucking pond water
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.